Recursion Pharmaceuticals Management
Management criteria checks 1/4
Recursion Pharmaceuticals' CEO is Chris Gibson, appointed in Nov 2013, has a tenure of 11.17 years. total yearly compensation is $8.61M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 1.8% of the company’s shares, worth $48.78M. The average tenure of the management team and the board of directors is 1.6 years and 10.4 years respectively.
Key information
Chris Gibson
Chief executive officer
US$8.6m
Total compensation
| CEO salary percentage | 6.5% |
| CEO tenure | 11.2yrs |
| CEO ownership | 1.8% |
| Management average tenure | 1.6yrs |
| Board average tenure | 10.4yrs |
Recent management updates
Recent updates
Recursion: Investors Will Need To Be Patient
Jan 10Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Dec 25
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Dec 09Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Nov 20Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week
Nov 10Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk
Nov 08Recursion: AI Is Only As Good As The Data
Sep 11Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Sep 04Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
Jun 24Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$378m |
| Jun 30 2024 | n/a | n/a | -US$375m |
| Mar 31 2024 | n/a | n/a | -US$354m |
| Dec 31 2023 | US$9m | US$561k | -US$328m |
| Sep 30 2023 | n/a | n/a | -US$293m |
| Jun 30 2023 | n/a | n/a | -US$260m |
| Mar 31 2023 | n/a | n/a | -US$249m |
| Dec 31 2022 | US$6m | US$498k | -US$239m |
| Sep 30 2022 | n/a | n/a | -US$247m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$212m |
| Dec 31 2021 | US$674k | US$485k | -US$186m |
| Sep 30 2021 | n/a | n/a | -US$147m |
| Jun 30 2021 | n/a | n/a | -US$124m |
| Mar 31 2021 | n/a | n/a | -US$99m |
| Dec 31 2020 | US$3m | US$270k | -US$87m |
Compensation vs Market: Chris's total compensation ($USD8.61M) is above average for companies of similar size in the US market ($USD6.62M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Gibson (41 yo)
11.2yrs
Tenure
US$8,613,208
Compensation
Dr. Christopher C. Gibson, Ph.D. also known as Chris, is Director of Cellino Biotech, Inc. from October 2024. Dr. Gibson is a Co-Founder of Recursion Pharmaceuticals Inc and serves as its Chief Executive O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.2yrs | US$8.61m | 1.8% $ 48.8m | |
| Co-Founder & Independent Director | 11.2yrs | US$300.25k | 0.81% $ 21.9m | |
| Co-Founder & Director | 12yrs | US$292.74k | 1.79% $ 48.5m | |
| Chief Medical Officer | 1.6yrs | US$4.53m | 0.014% $ 370.7k | |
| CFO & President of Recursion UK | less than a year | no data | 0.015% $ 402.4k | |
| Chief Operating Officer | less than a year | no data | no data | |
| Vice President of Finance & Accounting | no data | no data | no data | |
| Chief Technology Officer | 5yrs | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior Director of Investor Relations | 2.7yrs | no data | no data | |
| Chief Legal Officer & General Counsel | 1.3yrs | no data | no data | |
| Chief People and Impact Officer | less than a year | no data | no data |
1.6yrs
Average Tenure
47yo
Average Age
Experienced Management: RXRX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.2yrs | US$8.61m | 1.8% $ 48.8m | |
| Co-Founder & Independent Director | 11.2yrs | US$300.25k | 0.81% $ 21.9m | |
| Co-Founder & Director | 12yrs | US$292.74k | 1.79% $ 48.5m | |
| Chief R&D Officer | less than a year | no data | no data | |
| Member of Business Advisory Panel | 10.2yrs | no data | no data | |
| Member of Business Advisory Panel | 10.6yrs | no data | no data | |
| Chairman of Therapeutics Advisory Board | 3.5yrs | no data | no data | |
| Independent Chairman | 4.8yrs | US$302.74k | 0.0098% $ 265.7k | |
| Independent Director | 6.4yrs | US$21.25k | 0.0024% $ 64.6k | |
| Member of Scientific and Technical Advisory Board | 10.8yrs | no data | no data | |
| Member of Scientific & Technical Advisory Board | 10.8yrs | no data | no data | |
| Independent Director | 8.3yrs | US$307.74k | 0.024% $ 654.0k |
10.4yrs
Average Tenure
60yo
Average Age
Experienced Board: RXRX's board of directors are seasoned and experienced ( 10.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 22:53 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Recursion Pharmaceuticals, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gal Munda | Berenberg |
| Gaurav Goparaju | Berenberg |
| Alec Stranahan | BofA Global Research |